• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Journal of Pharmacology and Experimental Therapeutics

    Journal of Pharmacology and Experimental Therapeutics

    JournalISSN 0022-3565eISSN 1521-0103中科院 医学 3区

    年发文量

    研究主题

    论文(38079)

    排序
    1MSH2 Activates GOLPH3-Dependent Golgi Dispersal to Promote Irinotecan Resistance in Colorectal Cancer Via Enhanced Drug Efflux
    Jiabin Du, Bingchen Lin, Zhudong Chen, Wangwu Liu,Yuze Wu, Ling Zeng, Jianjun Meng,Yi Qiu,Chunxiao Wang,Chengzhi Qiu,Zhongshi Hong
    2026
    引用
    AI阅读
    加入学术空间
    2Ultrasound-Responsive Nanobubbles Synergize Chemo-Immunotherapy for Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment
    Yao Ma, Jian Yang,Yunlei Zou, Chujun Zhang,Mengting Zhang,Chaoqi Liu, Yun Liu, Yun Zhao
    2026
    引用
    AI阅读
    加入学术空间
    3Targeting Adipose Thermogenesis Preserves Cerebral Perfusion and Cognition During Early Metabolic Dysfunction: Functional, Molecular and Proteomic Insights
    Alaa Y. Soliman,Heba-Tallah Abd Elrahim Abd Elkader,Marwa Y. Sallam, Omar A. Soliman,Nefertiti El-Nikhely,Md Mostofa Al Amin Bhuiyan,Waziha Purba,Mojibola Fowowe,Oluwatosin Daramola,Judith Nwaiwu, Mahmoud Agami,Sahar M. El-Gowilly,
    2026
    引用
    AI阅读
    加入学术空间
    4The Phosphodiesterase 4B Inhibitor A33 Blocks Locomotor Stimulation by Low Doses of Ethanol and Diazepam
    Yuri A. Blednov,Sonia Mason,Jody Mayfield, Sindhu Sriramoji-Virdi,Miriam E. Bocarsly,Robert O. Messing

    Nonselective phosphodiesterase type 4 (PDE4) inhibitors (subtypes A–D) such as apremilast significantly reduce voluntary ethanol consumption. The PDE4B inhibitor A33 does not alter apremilast-mediated reductions in drinking but does alter recovery from intoxicating doses of ethanol in C57BL/6J mice. Here, we used A33 to test the hypothesis that PDE4B modulates the effects of low doses of ethanol. A33 (1 mg/kg, i.p.) prevented locomotor stimulation induced by 1.25 and 1.5 g/kg ethanol during the daytime, when mouse activity is normally low, and blocked stimulation by 1.25 g/kg ethanol in the open field. In other behavioral tests, A33 prevented the motivation to escape a stressful situation (hole-board test) and exploratory activity by 1.25 g/kg ethanol (spontaneous alternation test). However, A33 did not alter the anxiolytic effect of 1.25 g/kg ethanol in the elevated plus maze or working memory in the spontaneous alternation test. Similarly, A33 prevented locomotor stimulation by low-dose diazepam (1 mg/kg, i.p.) without altering its anxiolytic effect. Neurochemically, A33 blocked ethanol-evoked dopamine release in the nucleus accumbens, consistent with the behavioral finding that it blocks ethanol-induced locomotor stimulation. Together with evidence that A33 accelerates recovery from intoxication without altering acute tolerance or metabolism, these findings suggest that A33 specifically blocks the stimulant-like properties of low-dose ethanol. Significance Statement Apremilast nonselectively inhibits phosphodiesterase type 4 (PDE4) subtypes A–D and reduces alcohol drinking in preclinical and human studies. We use subtype-selective inhibitors to identify the subtype(s) driving anti-drinking effects. The PDE4B inhibitor A33 blocked motor stimulation by low-dose alcohol, which may explain its ability to shorten intoxication. A33 also blocked alcohol-induced dopamine release in a central area of the brain’s reward system. A33 may prevent stimulatory behaviors associated with alcohol-induced euphoria in humans, which may reduce drinking.

    2026
    引用
    AI阅读
    加入学术空间
    5Antinociceptive Interaction of 0 9-Tetrahydrocannabinol and Cannabidiol in a Humanized Mouse Model of Sickle Cell Disease
    Alex Mabou Tagne, Olufunke Florence Ajeigbe, Heidi C. Avalos,Francesca Galvani,Saeed Al Masri, Carolina Mireles,Kalpna Gupta,Daniele Piomelli

    Sickle cell disease (SCD) is characterized by recurrent, debilitating pain. Opioid analgesics are routinely used in its management, but limited efficacy and pervasive side effects prompt many patients with SCD to seek alternatives, including cannabis. Prior work has shown that 2 major cannabis constituents, 09-tetrahydro-cannabinol (0 9-THC) and cannabidiol (CBD), exert antinociceptive effects in HbSS-BERKmice, a model of SCD. The present study investigated the pharmacological interaction between these 2 agents and characterized the effects associated with repeated coadministration. Fixed-ratio isobolographic analyses demonstrated that 0 9-THC and CBD produced dose-dependent antinociception following acute coadministration. Fixed-ratio isobolographic analyses showed that the experimentally determined median effective dose of the mixture was lower than the theoretical additive dose, but the difference was not statistically significant, supporting an additive antinociceptive interaction. Repeated coadministration maintained antinociceptive efficacy over 14 days and reduced SCD-evoked anxiety-like behavior in one cohort but did not improve recognition-memory deficits. Liquid chromatography-tandem mass spectrometry analyses revealed that repeated coadministration increased plasma CBD concentrations, produced a modest increase in 0 9-THC exposure, and markedly elevated circulating levels of the endocannabinoid 2-arachidonoyl-sn-glycerol. Molecular analyses of spinal cord tissue showed that HbSS-BERK mice exhibited increased oxidative stress (malondialdehyde, MDA) and proinflammatory signaling (interleukin [IL]-13 mRNA), with no change in antiinflammatory signaling (IL-10 mRNA). Following 14 days of treatment, CBD reduced MDA and IL-13 transcription, whereas 0 9-THC reduced MDA and increased IL-10. Notably, the combination treatment simultaneously reduced oxidative stress, suppressed IL-13, and enhanced IL-10. Together, these findings demonstrate an additive antinociceptive interaction between 0 9-THC and CBD and sustained efficacy during repeated administration in SCD mice. Significance Statement: Chronic pain in sickle cell disease remains difficult to treat, and many patients use cannabis despite limited understanding of how its constituents interact to produce analgesia. This study demonstrates that the 2 major phytocannabinoids in cannabis, 09-tetrahydrocannabinol and cannabidiol, produce additive antinociceptive effects in a humanized mouse model of sickle cell disease, and their combined efficacy is maintained during repeated administration without detectable tolerance. (c) 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 38079 篇论文

    高被引作者

    作者引用发文
    j t litchfield1261014
    James H. Woods8339118
    Billy R Martin788657
    Frank Porreca649367
    Erminio Costa634959
    Wz Potter63495
    Y Sugiyama629563
    George Breese628657
    Parkhurst a Shore596914
    Solomon H. Snyder567333

    高产作者

    作者引用发文
    James H. Woods8339118
    Charles France291492
    Edwin K. Jackson316779
    Frank Porreca649367
    Curtis D Klaassen551267
    Y Sugiyama629563
    Kenner C. Rice225161
    Erminio Costa634959
    Billy R Martin788657
    George Breese628657

    相关期刊

    British Journal Of Pharmacology
    Fundamental & clinical pharmacology
    Expert opinion on therapeutic targets
    Basic & clinical pharmacology & toxicology
    Handbook of experimental pharmacology
    Pharmacology research & perspectives
    Pharmacological Reviews
    Annual Review of Pharmacology and Toxicology
    Trends in Pharmacological Sciences
    Molecular Pharmacology